Alamar Biosciences Q3 revenue rises 68% to $33.5 million; raises 2026 revenue guidance
Alamar Biosciences reported third-quarter 2026 revenue of $33.5 million, up 68% from a year earlier, and raised its full-year 2026 revenue guidance to $121 million to $123 million. The net loss widened to $13.3 million from $8.0 million as operating expenses rose 81%, though per-share loss narrowed to $0.19 from $0.69 on a much larger share count. President Tod White, who previously served as chief financial officer, will retire at the end of 2026 and remain a consultant through June 30, 2027.
Key points
- Q3 2026 total revenue was $33.5 million, up from $19.9 million; consumable revenue was $17.8 million.
- Full-year 2026 revenue guidance raised to $121 million to $123 million, from the prior $116 million to $120 million.
- Net loss was $13.3 million versus $8.0 million a year earlier; operating expenses were $35.8 million, up 81%.
- President Tod White retires December 31, 2026; he will consult from January 1, 2027 through June 30, 2027.
The filing
Written by AI on Nov 9, 2026, 11:48 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 03, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.